TI-Trust’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.33M Buy
23,089
+49
+0.2% +$2.81K 0.72% 43
2026
Q1
$1.4M Buy
23,040
+326
+1% +$19K 0.83% 36
2025
Q4
$1.23M Buy
22,714
+77
+0.3% +$3.7K 0.76% 42
2025
Q3
$1.02M Hold
22,637
0.64% 45
2025
Q2
$1.05M Hold
22,637
0.7% 43
2025
Q1
$1.38M Hold
22,637
0.91% 32
2024
Q4
$1.28M Hold
22,637
0.86% 32
2024
Q3
$1.17M Hold
22,637
0.84% 35
2024
Q2
$940K Hold
22,637
0.72% 40
2024
Q1
$1.23M Hold
22,637
0.9% 32
2023
Q4
$1.16M Hold
22,637
1.03% 29
2023
Q3
$1.31M Buy
22,637
+89
+0.4% +$5.45K 1.25% 21
2023
Q2
$1.44M Hold
22,548
1.33% 22
2023
Q1
$1.56M Buy
22,548
+85
+0.4% +$6K 1.47% 19
2022
Q4
$1.62M Hold
22,463
1.54% 18
2022
Q3
$1.6M Buy
22,463
+375
+2% +$27.2K 1.72% 17
2022
Q2
$1.7M Hold
22,088
1.75% 15
2022
Q1
$1.61M Hold
22,088
1.47% 19
2021
Q4
$1.38M Buy
+22,088
New +$1.3M 1.23% 22
2019
Q4
$1.42M Buy
+22,088
New +$1.26M 1.4% 18

Other funds holding BMY

TI-Trust's BMY Position: Q2 2026 in Review

TI-Trust increased its Bristol-Myers Squibb (BMY) stake by 0.21% in Q2 2026, buying an estimated $2.81K and bringing the position to 23,089 shares worth $1.33M. The position accounts for 0.72% of the portfolio, ranked #43.

TI-Trust first reported a position in BMY in Q4 2019 and has held it in 20 quarters since. The position peaked at $1.7M in Q2 2022. 885 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • TI-Trust held 23,089 shares of Bristol-Myers Squibb worth $1.33M as of Q2 2026.
  • TI-Trust bought 49 Bristol-Myers Squibb shares in Q2 2026, an estimated $2.81K.
  • Bristol-Myers Squibb made up 0.72% of TI-Trust's portfolio in Q2 2026, its #43 holding.
  • TI-Trust first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 20 quarters since.
  • TI-Trust's Bristol-Myers Squibb position peaked at $1.7M in Q2 2022.
  • 885 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on TI-Trust's 13F filing for Q2 2026, filed 23 Jul 2026.